In this study, molecular dynamics (MD) simulations and first-principles quantum mechanical/molecular mechanical free energy (QM/MM-FE) calculations have been performed to uncover the fundamental reaction pathway of proteasome with a representative inhibitor syringolin A (SylA). The calculated results reveal that the reaction process consists of three steps. profile demonstrates that the second step should be the rate-determining step and has the highest free energy barrier of 24.6 kcal/mol, which is reasonably close to the activation free energy (~22.4 -23.0 kcal/mol) derived from available experimental kinetic data. In addition, our computational results indicate that no water molecule can assist the rate-determining step, since the second step is not involved a proton transfer process. The obtained mechanistic insights should be valuable for understanding the inhibition process of proteasome by SylA and structurally related inhibitors at molecular level, and thus provide a solid mechanistic base and valuable clues for future rational design of novel, more potent inhibitors of proteasome.
Introduction
Proteasome, which contains a catalytic core particle (i.e. 20S proteasome) and two regulatory particles (i.e. 19S 'cap' regulatory complexes), is the major component of the nonlysosomal protein degradation pathway. 1 In eukaryotic and prokaryotic cells, ubiquitin can be attached to proteins and label them for destruction, then the proteins can be recognized by 19S regulatory complex and degraded by 20S proteasome. 2 This ubiquitin-proteasome pathway plays a primary role in the degradation of most proteins and removing the misfolded proteins in cells. 3 Recently, it was also found that the proteasome inhibitors have powerful anti-cancer activity, and several proteasome inhibitors designed according to the regulation mechanism of the proteasome system in vivo have been applied to the medical field. [4] [5] [6] [7] For example, the proteasome inhibitor bortezomib has been used in clinic for the treatment of multiple myeloma. 8 Moreover, some of the early proteasome inhibitors have contributed to the development of new anti-cancer drugs, such as CEP-18770, Carfilzomib, and NPI-0052. 4 More recently, a new strategy to use HIV protease-mediated activation of sterically capped proteasome inhibitor has been investigated for selectively killing the HIV-infected cells. 9 All of these facts demonstrate that proteasome inhibitors should be useful in the design of new anti-cancer tools and future therapeutics.
Due to the special anti-cancer activity, much attention has been paid to the development of proteasome inhibitors over the past decade. Thus far, there have been many kinds of proteasome inhibitors in the references, including peptide aldehydes, 10, 11 arecoline oxide tripeptides, 12, 13 retro hydrazino-azapeptoids, 14 proline-and arginine-rich peptides, 15 dipeptidyl boronates, 16 dipeptidyl boronic acids, [17] [18] [19] β-lactones, [20] [21] [22] epoxyketones, [23] [24] [25] [26] vinyl sulfones, [27] [28] [29] substituted vinyl ketones, 30 α,β-unsaturated N-acylpyrrole peptidyl derivatives, 31 cyclic peptides, 32, 33 and so on. 34 According to their chemical properties, the proteasome inhibitors can be mainly grouped into several types, and each type has a unique binding mode with the active sites of proteasome.
1, [35] [36] [37] [38] Among various kinds of proteasome inhibitors, there are both non-covalent and covalent binding inhibitors. To the best of our knowledge, all of the current clinical inhibitors form a covalent bond with proteasome during the inhibition process. Although there have been many experimental reports on proteasome inhibitors, 39, 40 the detailed reaction mechanism concerning how proteasome is inhibited by a covalent inhibitor has not been understood very well, so extensive computational studies on the complicated proteasome-inhibitor reactions at molecular level are very valuable.
The catalytic core particle of proteasome (i.e. 20S proteasome) is composed of 28 subunits arranged in a unit as four homoheptameric rings (α7β7β7α7), and each homoheptameric ring contains seven different subunits. 41 There are three types of proteasome β-type subunits, i.e. β1, β2, and β5 that have caspase-like (C-L), trypsin like (T-L), and chymotrypsin-like (CT-L) activities, respectively. 35 So, a total of six active sites of proteasome, including two β1 sites, two β2 sites, and two β5 sites, are functionally independent. All of them have an N-terminal threonine residue (Thr1) which can initiate a nucleophilic attack on substrate protein, small peptide or inhibitor. The X-ray crystal structures show the binding mode of proteasome with the product, 10, 20, 21, 30, 32, [42] [43] [44] [45] but it cannot determine the detailed reaction process. Although the inhibition mechanism of proteasome by epoxomicin (EPX) has been investigated in our previous work, 46 the detailed reaction mechanisms concerning how proteasome is inhibited by other types of covalent inhibitors (such as peptide aldehydes, boronic acid inhibitors, β-lactones, substituted vinyl sulfones, and substituted vinyl ketones) have still been unknown so far. As a natural product, Syringolin A (SylA, depicted in Scheme 1) was identified as a virulence factor in the plant-pathogen interaction, and has been found that it irreversibly inhibits all of the three catalytic activities of eukaryotic proteasomes. 30 SylA is an α,β-unsaturated lactam in which the amide group cannot be hydrolyzed by proteasome. As a proteasome inhibitor, SylA was recently shown to be a powerful tool to inhibit proliferation and induce apoptosis in neuroblastoma and ovarian cancer cells. 47 Thus, understanding the inhibition process of proteasome by SylA should be helpful for the research community to understand the inhibitions of proteasome by many α,β-unsaturated lactam inhibitors, and to rationally design more specific, selective and efficient new inhibitors of proteasome. This prompted us to study the detailed inhibition mechanism of proteasome by the representive α,β-unsaturated lactam SylA.
Scheme 1
The inhibition of proteasome by α,β-unsaturated lactam SylA.
In this study, the inhibitor SylA, which can irreversibly react with the Thr1 residue in the active site of the β5 subunit in proteasome by the Michael-addition reaction (depicted in Scheme 1), 30 was chosen as the substrate of proteasome, and the possible inhibition reaction pathway has been explored by performing molecular dynamics (MD) simulations and first-principles quantum mechanical/molecular mechanical (QM/MM)-free energy (QM/MM-FE) calculations. By using the QM/MM-FE approach, first-principles QM/MM reaction-coordinate calculations were followed by free energy perturbation (FEP) simulations to account for the dynamic effects of the protein environment on the free energy profile for the reaction pathway. Our QM/MM-FE calculations were based on the pseudobond first-principles QM/MM approach [48] [49] [50] and the revised pseudobond QM/MM-FE implementation.
51-56
The computational results clearly reveal the details of the enzymatic reaction pathway and its corresponding free energy profile. Based on the calculated free energy profile for the reaction process, the rate-determining step is identified.
And the roles of essential residues and substrate are discussed on the basis of the QM/MMoptimized geometries. Computational Methods MD Simulation. The X-ray crystal structure of proteasome-inhibitor (SylA) complex (PDB ID: 2ZCY, with a resolution of 2.9 Å) was employed to construct the initial structure of the enzyme-reactant (ER) complex. 30 In the X-ray crystal structure, the covalent bond between Thr1 and SylA was broken, and the missing atoms of SylA were added. According to our previous work, 46 the terminal amino group should be neutral in the active form of the proteasome.
However, it is not evident why the terminal amino group of Thr1 should be neutral because an amino group in water usually has a pKa of ~9. In order to verify the choice of protonation state of the terminal amino group, the pKa values of the active-site residues were calculated by using PROPKA method 57 implemented in the PROPKA3 software package. 58 The PROPKA method is capable of predicting pKa shifts of active-site residues and ionizable groups in protein-ligand complexes. Using the PROPKA method, the pKa of the terminal amino group of Thr1 was calculated to be 5.35, supporting the neutral state of the terminal amino group at pH 7. For the histidine residues, hydrogens were placed at the δ-position for His10, His178, His196, His278, His364, and at the ε-position for His237 and His259. The standard protonation states at pH 7 were used for other residues.
The restrained electrostatic potential (RESP) charges were used as the atomic charges of the substrate SylA in the MD simulation and the subsequent QM/MM calculations. The electrostatic potential used to obtain the RESP charges was calculated at the HF/6-31G* level using the Gaussian03 program, 59 and then the RESP charges were determined by fitting with the standard RESP procedure implemented in the Antechamber module of the Amber11 program. 60 As described in our previous studies, 24 the initial structure of ER was also constructed by retaining only two subunits (β5 and β6) and inhibitor SylA. Briefly, the MD simulations were performed using the Sander module of Amber (version 11) with Amber ff03 force field. Four chloride ions were added to neutralize the ER complex. After that, the ER complex was solvated in an orthorhombic box of TIP3P water molecules 61 with a minimum solute-wall distance of 10 Å. A ~10 ns MD simulation of the solvated system was performed in the same way described in our previous computational study. 62 Because the structure of the last snapshot in the MD simulation was close to the average structure simulated, the last snapshot of the MD-simulated structure was used as the initial structure for the first-principles QM/MM calculations. The used boundary of the QM-MM system for the whole reaction is depicted in the figures discussed below, and the QM/MM interface was treated by using a pseudobond approach. [48] [49] [50] Before the QM/MM geometry optimization, the initial structure of the entire reaction system was energy-minimized with the MM method by using the AMBER11
program, 60 and the convergence criterion for energy gradient of 0.1 kcal·mol
was achieved.
A reaction-coordinate driving method and an iterative energy minimization procedure were applied to determine the reaction pathway by the pseudobond QM/MM calculations. 48 The step size used to scan the reaction coordinates was 0.1 Å. In the QM/MM calculations, we performed the QM calculations at the B3LYP/6-31G* level of theory by using a modified version 51 of Gaussian03 program, 59 and carried out the MM calculation by using a modified version 51 of the AMBER8 program. . In all the QM/MM calculations, the atoms within 20 Å of C 1 atom in the reaction center (Scheme 1) were allowed to move while the other atoms were kept frozen.
It should also be noted that the QM and MM subsystems were energy-minimized iteratively during the QM/MM geometry optimization. For each step of the iteration, the MM subsystem was kept frozen during the QM subsystem minimizations, whereas the QM subsystem was kept frozen when the MM subsystem was energy-minimized. 
Results and Discussion

MD simulation results
Based on our previous work, indicating that the key distances in the reaction center should be proper for the inhibition process.
In light of the results obtained from the X-ray crystal structure and MD simulation, and our previously study on the inhibition mechanism of proteasome by EPX, 46 we may reasonably assume that Thr1-O 
Fundamental reaction pathway of the inhibition
The QM/MM optimized ER structure of the enzyme-SylA reaction system was employed as the starting point of the QM/MM reaction-coordinate calculations, which were performed at the B3LYP/6-31G*:AMBER level to determine the minimum-energy reaction pathway. As states, and product EP existing in the inhibition reaction process. In Fig. 1A , the atoms with blue color were treated by QM method, the boundary carbon atoms with red color were treated with the improved pseudobond parameters, and the other atoms of the entire reaction system were considered as MM subsystem during the QM/MM calculations. and RH -C2 were chosen to represent the reaction coordinate as RNz-H  -RH -C2 for the current reaction step. In TS3 (Fig. 2C) , the distances RNz-H  and RH -C2 are 1.18 and 1.73 Å, respectively.
In this step, the product EP is generated via transition state TS3, indicating that the Michael-type addition on the olefin is completed.
Free energy profile for the fundamental inhibition reaction pathway
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Organic & Biomolecular Chemistry Accepted Manuscript 13 As described above, the minimum-energy reaction pathway for the inhibition process calculated at the B3LYP/6-31G*:AMBER level contains three reaction steps. To determine the corresponding free energy profile of the reaction, we performed QM/MM single-point energy calculations at a higher level (B3LYP/6-31++G**:AMBER) for each QM/MM optimized geometry along the obtained minimum-energy path. For each geometrical structure along the reaction path, the ESP charges determined in the QM part of the QM/MM single-point energy calculation were used in the subsequent FEP simulations to estimate the free energy changes. Fig. 3 is the free energy profile for this reaction process, which is determined by the QM/MM-FE calculations first without the zero-point and thermal corrections for the QM subsystem, and then with the zero-point and thermal corrections for the QM subsystem (values given in parentheses). As shown in Fig. 3 , without the zero-point and thermal corrections for the QM subsystem, the free energy barriers calculated for the first to third reaction steps of the reaction pathway are 12.0, 16.5, and 0.3 kcal/mol, respectively. With the zero-point and thermal corrections for the SylA is an irreversible proteasome inhibitor.
Depicted in
Based on the free energy profile depicted in Fig. 3 , the free energy barrier for the entire reaction process is determined by that (24.6 kcal/mol) for the second reaction step (the ratedetermining step). We wanted to know whether the calculated free energy barrier of 24. 
Conclusion
In this study, the detailed mechanism for the inhibition reaction of proteasome (catalytic subunit β5) with SylA has been investigated by carrying out the first-principles QM/MM-FE calculations. Based on the results from the QM/MM calculations, the reaction process consists of The calculated free energy profile of the reaction process indicates that the free energy barriers for the first and second reaction steps are 9.8 and 17.3 kcal/mol, respectively, whereas the third reaction step is a barrierless process. The free energy barrier of the entire inhibition reaction process should be the free energy difference between the lowest-energy state ER and the highest-energy state TS2 (24.6 kcal/mol), indicating that the second step should be the ratedetermining step of the inhibition reaction process. Our calculated results also indicate that no water molecule can assist the rate-determining step (i.e. the second step), since this reaction step does not involve a proton transfer. The calculated free energy barrier of 24.6 kcal/mol for the rate-determining step is reasonably close to the experimentally derived free energy barrier of ~22.4 -23.0 kcal/mol, suggesting that our calculated results are reasonable. Further, the computational results demonstrate that the reverse reaction should be extremely slow and, thus, the nucleophilic attack of Thr1-O  on the olefin should be irreversible, which is qualitatively consistent with the experimental observation. The computational insights obtained should be valuable not only for understanding the detailed inhibition reaction mechanism of proteasome by α,β-unsaturated lactam SylA, but also for the future rational design of novel, more potent inhibitors of proteasome.
